Depemokimab: Acceptance of regulatory submissions in EU/China/Japan (based on SWIFT-1 and SWIFT-2 trials) for asthma in H1 2025 (GSK) - Jul 31, 2024 - Q2 2024 Results: Acceptance of regulatory submissions in EU/China/Japan (based on ANCHOR-1 and ANCHOR-2 trials) for chronic rhinosinusitis with nasal polyps in H1 2025
China filing • EMA filing • Japan filing • Chronic Rhinosinusitis With Nasal Polyps • Immunology
|